2026-05-24

HY spreads at distress levels — 700bps, recession-associated

FDA approves TEFLARO (AbbVie) — new revenue stream

FDA approves KALETRA (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves KALETRA (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves DALVANCE (AbbVie) — new revenue stream

FDA approves NORVIR (AbbVie) — new revenue stream

FDA approves TEFLARO (AbbVie) — new revenue stream

FDA approves DALVANCE (AbbVie) — new revenue stream

FDA approves KALETRA (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves DALVANCE (AbbVie) — new revenue stream

FDA approves NORVIR (AbbVie) — new revenue stream

FDA approves ACULAR LS (AbbVie) — new revenue stream

FDA approves TEFLARO (AbbVie) — new revenue stream

FDA approves ACULAR LS (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves ACULAR LS (AbbVie) — new revenue stream

FDA approves NORVIR (AbbVie) — new revenue stream

FDA approves ZITHROMAX (PFIZER) — new revenue stream

FDA approves PREPIDIL (PFIZER) — new revenue stream

FDA approves LORBRENA (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves LORBRENA (PFIZER) — new revenue stream

FDA approves LOMOTIL (PFIZER) — new revenue stream

FDA approves PREPIDIL (PFIZER) — new revenue stream

FDA approves PREPIDIL (PFIZER) — new revenue stream

FDA approves DEPO-MEDROL (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves ZITHROMAX (PFIZER) — new revenue stream

FDA approves ZITHROMAX (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves LOMOTIL (PFIZER) — new revenue stream

FDA approves ZITHROMAX (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves DEPO-MEDROL (PFIZER) — new revenue stream

FDA approves ZITHROMAX (PFIZER) — new revenue stream

FDA approves DEPO-MEDROL (PFIZER) — new revenue stream

FDA approves ZITHROMAX (PFIZER) — new revenue stream

FDA approves LOMOTIL (PFIZER) — new revenue stream

FDA approves LORBRENA (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

FDA approves drug (PFIZER) — new revenue stream

Missed consensus by 46.0% — EPS $0.1 vs $0.1851 estimate

Missed consensus by 475.4% — EPS $-0.11 vs $0.0293 estimate

Missed consensus by 475.4% — EPS $-0.11 vs $0.0293 estimate

Missed consensus by 46.0% — EPS $0.1 vs $0.1851 estimate

Beat consensus by 11.0% — EPS $-0.1 vs $-0.1124 estimate

Missed consensus by 100.7% — EPS $-0.17 vs $-0.0847 estimate

Beat consensus by 35.2% — EPS $-0.08 vs $-0.1234 estimate

Missed consensus by 636.7% — EPS $-0.19 vs $0.0354 estimate

Missed consensus by 73.8% — EPS $0.04 vs $0.1524 estimate

Missed consensus by 1017.0% — EPS $-0.21 vs $-0.0188 estimate

Missed consensus by 2658.6% — EPS $-0.16 vs $-0.0058 estimate

Beat consensus by 42.3% — EPS $0.04 vs $0.0281 estimate

Beat consensus by 30.7% — EPS $0.04 vs $0.0306 estimate

Missed consensus by 21.9% — EPS $0.01 vs $0.0128 estimate

Beat consensus by 18.6% — EPS $-0.39 vs $-0.4794 estimate

Beat consensus by 18.3% — EPS $-0.3 vs $-0.3672 estimate

Beat consensus by 23.3% — EPS $-0.36 vs $-0.4692 estimate

Beat consensus by 19.1% — EPS $-0.4 vs $-0.4947 estimate

Missed consensus by 22.0% — EPS $0.26 vs $0.3333 estimate

Beat consensus by 10.3% — EPS $0.39 vs $0.3535 estimate

Beat consensus by 52.0% — EPS $0.54 vs $0.3553 estimate

Beat consensus by 32.8% — EPS $0.45 vs $0.3388 estimate

Beat consensus by 47.2% — EPS $0.647 vs $0.4394 estimate

Beat consensus by 94.1% — EPS $0.882 vs $0.4545 estimate

Missed consensus by 42.3% — EPS $0.513 vs $0.8888 estimate

Missed consensus by 9.6% — EPS $-0.36 vs $-0.3284 estimate

Beat consensus by 7.3% — EPS $-0.26 vs $-0.2805 estimate

Beat consensus by 69.0% — EPS $2.11 vs $1.2484 estimate

Missed consensus by 242.3% — EPS $-0.44 vs $0.3091 estimate

Missed consensus by 10.0% — EPS $0.48 vs $0.5333 estimate

Missed consensus by 36.0% — EPS $0.53 vs $0.8282 estimate

Missed consensus by 43.8% — EPS $0.7 vs $1.246 estimate

Beat consensus by 29.1% — EPS $-0.55 vs $-0.7752 estimate

Beat consensus by 18.6% — EPS $-0.54 vs $-0.663 estimate

Beat consensus by 10.2% — EPS $-0.49 vs $-0.5457 estimate

Beat consensus by 47.4% — EPS $354.34 vs $240.4115 estimate

Beat consensus by 40.0% — EPS $297.32524 vs $212.384 estimate

Missed consensus by 30.2% — EPS $123.58 vs $176.9621 estimate

Beat consensus by 31.3% — EPS $211.46 vs $161.0916 estimate

Missed consensus by 54.1% — EPS $0.06 vs $0.1306 estimate

Beat consensus by 22.8% — EPS $0.16 vs $0.1303 estimate

Missed consensus by 30.6% — EPS $0.08 vs $0.1153 estimate

Beat consensus by 31.5% — EPS $-0.03 vs $-0.0438 estimate

Beat consensus by 47.6% — EPS $-0.03 vs $-0.0572 estimate

Missed consensus by 18.9% — EPS $-0.08 vs $-0.0673 estimate

Beat consensus by 267.1% — EPS $0.27 vs $-0.1616 estimate

Beat consensus by 8.5% — EPS $0.41 vs $0.378 estimate

Missed consensus by 128.7% — EPS $-13.4 vs $-5.858 estimate

Beat consensus by 978.4% — EPS $0.11 vs $0.0102 estimate

Missed consensus by 145.1% — EPS $-0.05 vs $-0.0204 estimate

Beat consensus by 178.4% — EPS $0.008 vs $-0.0102 estimate

Missed consensus by 222.5% — EPS $-0.05 vs $0.0408 estimate

Missed consensus by 41.5% — EPS $1.03 vs $1.7614 estimate

Beat consensus by 18.9% — EPS $2.5 vs $2.1033 estimate

Beat consensus by 26.0% — EPS $1.4 vs $1.111 estimate

Missed consensus by 48.0% — EPS $-0.61 vs $-0.4121 estimate

Beat consensus by 43.2% — EPS $-0.31 vs $-0.5457 estimate

Missed consensus by 41.2% — EPS $-0.73 vs $-0.5171 estimate

Beat consensus by 16.3% — EPS $-0.41 vs $-0.4898 estimate

Beat consensus by 7.8% — EPS $1.33 vs $1.2338 estimate

Beat consensus by 6.4% — EPS $1.27 vs $1.1935 estimate

Beat consensus by 11.1% — EPS $0.34 vs $0.306 estimate

Beat consensus by 25.1% — EPS $0.37 vs $0.2958 estimate

Beat consensus by 15.9% — EPS $0.39 vs $0.3366 estimate

Beat consensus by 7.2% — EPS $0.35 vs $0.3264 estimate

Beat consensus by 90.2% — EPS $-0.04 vs $-0.4094 estimate

Missed consensus by 11.4% — EPS $-0.49 vs $-0.4397 estimate

Beat consensus by 24.3% — EPS $0.52 vs $0.4183 estimate

Missed consensus by 7.6% — EPS $0.17 vs $0.184 estimate

Beat consensus by 218.0% — EPS $0.38 vs $0.1195 estimate

Missed consensus by 14.2% — EPS $0.36 vs $0.4198 estimate

Beat consensus by 197.0% — EPS $0.03 vs $0.0101 estimate

Missed consensus by 6.5% — EPS $0.99 vs $1.0585 estimate

Missed consensus by 256.3% — EPS $-0.16 vs $-0.0449 estimate

Missed consensus by 415.5% — EPS $-0.2 vs $-0.0388 estimate

Missed consensus by 149.1% — EPS $-0.07 vs $-0.0281 estimate

Missed consensus by 14.4% — EPS $-0.07 vs $-0.0612 estimate

Beat consensus by 21.3% — EPS $-2.65 vs $-3.366 estimate

Beat consensus by 38.8% — EPS $-2.55 vs $-4.1693 estimate

Missed consensus by 85.8% — EPS $-4.14 vs $-2.2287 estimate

Beat consensus by 37.9% — EPS $-0.73 vs $-1.1764 estimate

Beat consensus by 12.6% — EPS $-0.009 vs $-0.0103 estimate

Missed consensus by 100.0% — EPS $0 vs $0.0102 estimate

Beat consensus by 14.9% — EPS $0.01 vs $0.0087 estimate

Missed consensus by 34.6% — EPS $0.01 vs $0.0153 estimate

Beat consensus by 13.7% — EPS $5.2 vs $4.5744 estimate

Beat consensus by 486.8% — EPS $1732 vs $-447.7406 estimate

Missed consensus by 19.1% — EPS $-525 vs $-440.7978 estimate

Missed consensus by 110.7% — EPS $-41 vs $384.7093 estimate

Missed consensus by 268.0% — EPS $-712 vs $423.765 estimate

Beat consensus by 27.5% — EPS $1.89 vs $1.4818 estimate

Missed consensus by 7.4% — EPS $1.11 vs $1.1989 estimate

Missed consensus by 61.4% — EPS $0.27 vs $0.6996 estimate

Missed consensus by 7.1% — EPS $-0.59 vs $-0.5508 estimate

Missed consensus by 9.2% — EPS $-0.54 vs $-0.4947 estimate

Beat consensus by 32.5% — EPS $-0.42 vs $-0.6222 estimate

Beat consensus by 96.1% — EPS $0.02 vs $0.0102 estimate

Missed consensus by 492.2% — EPS $-0.04 vs $0.0102 estimate

Missed consensus by 47.1% — EPS $-0.06 vs $-0.0408 estimate

Beat consensus by 124.5% — EPS $0.01 vs $-0.0408 estimate

Beat consensus by 27.0% — EPS $0.07 vs $0.0551 estimate

Beat consensus by 24.1% — EPS $0.28 vs $0.2256 estimate

Beat consensus by 30.2% — EPS $0.44 vs $0.338 estimate

Beat consensus by 15.7% — EPS $0.79 vs $0.6827 estimate

Missed consensus by 14.8% — EPS $0.22 vs $0.2583 estimate

Beat consensus by 32.5% — EPS $0.12 vs $0.0906 estimate

Beat consensus by 508.2% — EPS $0.04 vs $-0.0098 estimate

Beat consensus by 94.7% — EPS $-0.01 vs $-0.1894 estimate

Missed consensus by 424.0% — EPS $-0.12 vs $-0.0229 estimate

Beat consensus by 7.4% — EPS $9.38 vs $8.7304 estimate

Beat consensus by 6.6% — EPS $1.39 vs $1.3043 estimate

Beat consensus by 10.7% — EPS $1.3 vs $1.1742 estimate

Beat consensus by 7.7% — EPS $1.41 vs $1.3092 estimate

Missed consensus by 4910.9% — EPS $-4.6 vs $-0.0918 estimate

Missed consensus by 236.1% — EPS $-0.48 vs $-0.1428 estimate

Missed consensus by 96.1% — EPS $-0.22 vs $-0.1122 estimate

Missed consensus by 6877.1% — EPS $-4.27 vs $-0.0612 estimate

Missed consensus by 298.0% — EPS $-0.02 vs $0.0101 estimate

Missed consensus by 32.0% — EPS $-0.35 vs $-0.2652 estimate

Beat consensus by 33.7% — EPS $0.75 vs $0.561 estimate

Beat consensus by 34.0% — EPS $0.23 vs $0.1717 estimate

Beat consensus by 16.9% — EPS $0.21 vs $0.1796 estimate

Beat consensus by 8.3% — EPS $0.19 vs $0.1755 estimate

Beat consensus by 18.3% — EPS $0.23 vs $0.1944 estimate

Missed consensus by 25.4% — EPS $-0.43 vs $-0.343 estimate

Missed consensus by 89.6% — EPS $-0.5 vs $-0.2637 estimate

Beat consensus by 6.8% — EPS $-0.45 vs $-0.4827 estimate

Beat consensus by 7.5% — EPS $0.69 vs $0.6419 estimate

Beat consensus by 14.2% — EPS $0.58 vs $0.508 estimate

Beat consensus by 8.6% — EPS $0.67 vs $0.6167 estimate

Missed consensus by 19.2% — EPS $0.4 vs $0.4949 estimate

Missed consensus by 29.6% — EPS $0.36 vs $0.5115 estimate

Beat consensus by 16.1% — EPS $0.52 vs $0.448 estimate

Beat consensus by 10.9% — EPS $0.6 vs $0.5409 estimate

Missed consensus by 19.0% — EPS $0.09 vs $0.1111 estimate

Missed consensus by 23.8% — EPS $0.1 vs $0.1313 estimate

Missed consensus by 35.9% — EPS $0.11 vs $0.1717 estimate

Gold volume spike — 257.2× the 20-day average (106,230 vs 413 avg)

Silver volume spike — 13.9× the 20-day average (25,615 vs 1,841 avg)

Copper volume spike — 18.0× the 20-day average (41,401 vs 2,303 avg)

Platinum volume spike — 258.6× the 20-day average (13,124 vs 50 avg)

OSINT: Uncertainty Surrounds Prospective Peace Deal

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC COPPER speculator at extreme long — contrarian bear signal

Saudi Arabia (Dhahran): drought conditions detected — potential oil supply impact

Cocoa volume spike — 2.5× the 20-day average (14,971 vs 6,107 avg)

Coffee volume spike — 2.8× the 20-day average (8,179 vs 2,897 avg)

OSINT: Exit Taxes Ineffective as States Face Fiscal Collapse

CFTC NATURAL GAS speculator at extreme long — contrarian bear signal

CFTC COPPER speculator at extreme long — contrarian bear signal

Fed net liquidity surged $207bn in 4 weeks — significant injection, risk-on tailwind